Journal
ECANCERMEDICALSCIENCE
Volume 8, Issue -, Pages -Publisher
CANCER INTELLIGENCE LTD
DOI: 10.3332/ecancer.2014.485
Keywords
drug repurposing; cimetidine; immunostimulant; ReDO project
Categories
Ask authors/readers for more resources
Cimetidine, the first H-2 receptor antagonist in widespread clinical use, has anti-cancer properties that have been elucidated in a broad range of pre-clinical and clinical studies for a number of different cancer types. These data are summarised and discussed in relation to a number of distinct mechanisms of action. Based on the evidence presented, it is proposed that cimetidine would synergise with a range of other drugs, including existing chemotherapeutics, and that further exploration of the potential of cimetidine as an anti-cancer therapeutic is warranted. Furthermore, there is compelling evidence that cimetidine administration during the peri-operative period may provide a survival benefit in some cancers. A number of possible combinations with other drugs are discussed in the supplementary material accompanying this paper.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available